Associate Professor of Neurology, Massachusetts General Hospital
Neurology
Dr. Scott R. Plotkin, MD
|
|
Give Review
Scott Plotkin is an expert in the field of Neurology. He graduated from Tulane University School of Medicine. Scott Plotkin is a published MD as well. He has 82 publications published. The latest was: Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Scott Plotkin is registered with Medicare.
Publications
- Laryngeal Manifestations of Neurofibromatosis.
- Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and Schwannomatosis.
- Anti-VEGF treatment improves neurological function and augments radiation response in NF2 Schwannoma model.
- Quality of life among children and adolescents with neurofibromatosis 1: a Systematic review of the literature.
- Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1.
- Examining perceived Cancer risk among patients with neurofibromatosis type 1.
- Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral Nervous system.
- Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
- Update from the 2013 international neurofibromatosis conference.
- The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and Schwannomatosis: results from a pilot study.
- Magnetic Resonance Imaging Observations in Primary Central Nervous System Lymphoma.
- Teaching NeuroImages: Brain mass with hilar adenopathy: The importance of histologic diagnosis.
- Long-term Toxicity of bevacizumab therapy in neurofibromatosis 2 patients.
- Chemoprevention for neurofibromatosis 2: just over the horizon?
- Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
- Turner syndrome and meningioma: Support for a possible increased risk of neoplasia in Turner syndrome.
- CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and Schwannomatosis toward the development of effective therapies.
- Posterior Reversible Encephalopathy Syndrome (PRES) Complicating Newly-Diagnosed Diffuse Large B-Cell Lymphoma.
- Natural history of vestibular Schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients.
- Hearing and facial function outcomes for neurofibromatosis 2 clinical trials.
- Achieving consensus for clinical trials: The REiNS International Collaboration.
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
- Anatomic and Metabolic Evaluation of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis 1 Using Whole-Body MRI and 18F-FDG PET Fusion.
- Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a Systematic review of the literature.
- Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
- Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
- Neurofibromatosis type 1 and pregnancy complications: a population-based study.
- Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.
- Role of resection of malignant peripheral Nerve sheath tumors in patients with neurofibromatosis type 1.
- Understanding relationships between autism, intelligence, and Epilepsy: a cross-disorder approach.
- Plasma S100? is not a useful biomarker for tumor burden in neurofibromatosis.
- Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated Gliomas to be spinal ependymomas.
- Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome.
- Bevacizumab for progressive vestibular Schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
- Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study.
- Chemotherapy:: present and future.
- Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis.
- Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
- Facial Reanimation of Patients with Neurofibromatosis Type 2.
- Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients.
- Exacerbation of Cerebral radiation necrosis by bevacizumab.
- Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.
- Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard...
- Erlotinib for progressive vestibular Schwannoma in neurofibromatosis 2 patients.
- Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
- Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related Tumors.
- Use of video to facilitate end-of-life discussions with patients with Cancer: a randomized controlled trial.
- NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and Schwannoma growth.
- Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
- Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular Schwannoma.
- Tumor burden in patients with neurofibromatosis types 1 and 2 and Schwannomatosis: determination on whole-body MR images.
- The Neurofibromatoses. Part 1: NF1.
- The neurofibromatoses. Part 2: NF2 and Schwannomatosis.
- Patient and physician attitudes regarding clinical trials in neurofibromatosis 1.
- Three-dimensional volumetrics for tracking vestibular Schwannoma growth in neurofibromatosis type II.
- Modeling NF2 with human arachnoidal and meningioma cell culture Systems: NF2 silencing reflects the benign character of tumor growth.
- Clinical reasoning: a case of multiple intraCerebral hemorrhages.
- Genetic causes of Brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes.
- Value of PET in the assessment of patients with neurofibromatosis type 1.
- Case records of the Massachusetts General Hospital. Case 11-2007. A 59-year-old man with neck Pain, weakness in the arms, and cranial-nerve palsies.
- Treatment of relapsed central Nervous system lymphoma with high-dose methotrexate.
- Neurologic complications of Cancer therapy.
- Primary Nervous system lymphoma.
- Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients.
- Folk remedy use in the inner city.
- Traumatic cervical spine disruption.
- Differential transport of rat and human interleukin-1alpha across the blood-Brain barrier and blood-testis barrier in rats.
- Withdrawal from alcohol in withdrawal seizure-prone and -resistant mice: evidence for enkephalin resistance.
- Identity analysis of Schwannomatosis kindreds with recurrent constitutional SMARCB1 (INI1) alterations.
- Genomic profiling distinguishes familial multiple and sporadic multiple Meningiomas.
- Advances in the therapy of primary central Nervous system lymphoma.
- AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, Normalizes tumor vasculature and alleviates edema in glioblastoma patients.
- Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial Schwannomatosis.
- Primary Nervous-system lymphoma.
- Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
- Diagnostic criteria for Schwannomatosis.
- Update on primary central Nervous system lymphoma.
- Facial numbness in a man with inguinal and retroperitoneal masses.
- Peripheral and cranial Nerve sheath tumors.
- Ramsay Hunt syndrome in a patient with metastatic lung cancer to Brain.
- Audiologic and radiographic response of NF2-related vestibular Schwannoma to erlotinib therapy.
Schools
Tulane University of Louisiana
MghBrigham and Women39s
Massachusetts General Hospital
Procedures Preformed
- EEG (Electroencephalogram)
- EMG (Electromyography)
Conditions Treated
- Alzheimer's Disease
- Ataxia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Aneurysm
- View All
Doctors Specialties
- Neurology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- GHI PPO
- Fallon Community Health Plan
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Network Health
- Tufts PPO
- UniCare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
Massachusetts General Hospital -
Tulane University -
Tulane University School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1699749390 | |
| NPPES Provider LastName | PLOTKIN | |
| NPPES Provider FirstName | SCOTT | |
| NPPES Provider ZIPCode | 02114 | |
| NPPES Provider State | MA | |
| Specialty Description | Neurology | |
| Total Claim Count | 42.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1699749390 |
| Last Name Of The Provider | PLOTKIN |
| First Name Of The Provider | SCOTT |
| View All |
Similar Doctors
|
|
Dr. Jorg Dietrich, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Altaf Saadi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fawn Leigh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carl L. Kramer, MD |
|
|
Dr. Frank H. Duffy, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Olga R. Rosenvald Szenberg, MD |
|
|
Dr. Stephen A. Vanhaerents, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael G. Schlossmacher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann M. Bergin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steve S. Han, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joe F. Jabre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joao Radvany, MD |
|
|
Dr. Roberta White, PHD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Luciana Catanese, MD |